AbbVie Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, filed on August 21, 2014, reports events occurring on August 18, 2014. The filing details the entry into material definitive credit agreements by AbbVie Inc. and its affiliates (AbbVie Holdings Private Limited and AbbVie Private Limited) to support a corporate combination transaction involving Shire.
Key Financial Metrics and Debt Obligations
The filing establishes two primary new debt facilities:
- Term Loan Facility: A £3.2 billion term loan facility entered into by AbbVie Holdings Private Limited. This facility reduces commitments under a prior bridge credit facility.
- Revolving Credit Facility: A $4.0 billion revolving credit facility entered into by AbbVie Inc. and AbbVie Private Limited.
Interest rates for both facilities are variable, based on either a Base Rate or Eurocurrency Rate plus an applicable margin ranging from 0.0% to 0.50% (Base Rate) or 0.625% to 1.50% (Eurocurrency), contingent on the public debt rating of New AbbVie.
Material Changes and Agreements
The primary material change is the execution of the Term Loan and Revolving Credit Agreements on August 18, 2014. Additionally, the 364-Day Bridge Credit Agreement dated July 17, 2014, was amended on August 11, 2014. The Term Loan Facility matures two years after its closing date, while the Revolving Credit Facility matures five years after its closing date, with a termination date of July 31, 2015, if the closing does not occur by then.
Outlook, Risks, and Contingencies
The credit agreements contain customary affirmative and negative covenants, including financial covenants, and events of default. The Revolving Credit Facility includes an automatic reduction of commitments to $3.0 billion upon the occurrence of an "acquisition cancellation." The filing notes that these agreements are subject to satisfaction of certain conditions precedent before advances can be made. Investors are directed to review the upcoming Proxy Statement/Prospectus on Form S-4 for further details on the combination transaction.
Key Facts for Investor Verification
- Verify the total debt load increase of approximately £3.2 billion (Term Loan) and $4.0 billion (Revolving Credit) pending closing conditions.
- Confirm the specific financial covenants and leverage ratios required under the new credit agreements.
- Monitor the status of the "acquisition cancellation" clause which could reduce the Revolving Credit Facility to $3.0 billion.
- Review the upcoming Form S-4 Proxy Statement/Prospectus for details on the Shire combination transaction.
- Note that the filing does not provide current revenue, profit, or cash flow figures; it focuses solely on the new debt obligations.